These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 1696939)

  • 1. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific.
    Pettersson A; Kuipers B; Pelzer M; Verhagen E; Tiesjema RH; Tommassen J; Poolman JT
    Infect Immun; 1990 Sep; 58(9):3036-41. PubMed ID: 1696939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes.
    Ala'Aldeen DA; Davies HA; Borriello SP
    Vaccine; 1994 May; 12(6):535-41. PubMed ID: 7518627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.
    Rosenqvist E; Musacchio A; Aase A; Høiby EA; Namork E; Kolberg J; Wedege E; Delvig A; Dalseg R; Michaelsen TE; Tommassen J
    Infect Immun; 1999 Mar; 67(3):1267-76. PubMed ID: 10024570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of the 98-kilodalton iron-regulated outer membrane protein of Neisseria meningitidis.
    Pettersson A; van der Ley P; Poolman JT; Tommassen J
    Infect Immun; 1993 Nov; 61(11):4724-33. PubMed ID: 8406871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains.
    Ala'Aldeen DA; Borriello SP
    Vaccine; 1996 Jan; 14(1):49-53. PubMed ID: 8821649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region.
    Kortekaas J; Pettersson A; van der Biezen J; Weynants VE; van der Ley P; Poolman J; Bos MP; Tommassen J
    Vaccine; 2007 Jan; 25(1):72-84. PubMed ID: 16914236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of meningococcal outer membrane protein vaccines solubilized with detergent or C polysaccharide.
    Poolman JT; Timmermans HA; Hopman CT; Teerlink T; Van Vught PA; Witvliet MH; Beuvery EC
    Antonie Van Leeuwenhoek; 1987; 53(6):413-9. PubMed ID: 3130780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.
    van der Voort ER; van der Ley P; van der Biezen J; George S; Tunnela O; van Dijken H; Kuipers B; Poolman J
    Infect Immun; 1996 Jul; 64(7):2745-51. PubMed ID: 8698504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine.
    Delvig AA; Wedege E; Caugant DA; Dalseg R; Kolberg J; Achtman M; Rosenqvist E
    Microbiology (Reading); 1995 Jul; 141 ( Pt 7)():1593-600. PubMed ID: 7551027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis.
    van der Ley P; van der Biezen J; Hohenstein P; Peeters C; Poolman JT
    Infect Immun; 1993 Oct; 61(10):4217-24. PubMed ID: 7691745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodalton transferrin receptor, and their potential for use as vaccines.
    Banerjee-Bhatnagar N; Frasch CE
    Infect Immun; 1990 Sep; 58(9):2875-81. PubMed ID: 2117572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
    Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
    Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface antigen analysis of group B Neisseria meningitis outer membrane by monoclonal antibodies: identification of bactericidal antibodies to class 5 protein.
    Danelli MG; Batoreu NM; Lacerda MD; Ferreira CR; Cardoso JD; Peralta JM; Frasch CE
    Curr Microbiol; 1995 Sep; 31(3):146-51. PubMed ID: 7545046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidate Neisseria meningitidis NspA vaccine.
    Martin D; Brodeur BR; Hamel J; Couture F; de Alwis U; Lian Z; Martin S; Andrews D; Ellis RW
    J Biotechnol; 2000 Sep; 83(1-2):27-31. PubMed ID: 11000456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of a murine monoclonal antibody specific for the P1.15 PorA proteins from vaccine strain B:4,7:P1.19,15 of Neisseria meningitidis.
    Pérez ME; Barberá R; Domínguez F; Otero O; Gutiérrez M; Falero-Diaz G; Sotolongo F; Sierra G
    Hybridoma (Larchmt); 2006 Aug; 25(4):243-7. PubMed ID: 16934022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and characterization of a new monoclonal antibody against Neisseria meningitidis: study of the cross-reactivity with different bacterial genera.
    De Gaspari EN
    Hybridoma; 2000 Dec; 19(6):445-53. PubMed ID: 11152396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants.
    Gómez JA; Criado MT; Ferreirós CM
    FEMS Immunol Med Microbiol; 1998 Jan; 20(1):79-86. PubMed ID: 9514578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine.
    Rosenqvist E; Høiby EA; Wedege E; Caugant DA; Frøholm LO; McGuinness BT; Brooks J; Lambden PR; Heckels JE
    Microb Pathog; 1993 Sep; 15(3):197-205. PubMed ID: 7505873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody.
    Brodeur BR; Larose Y; Tsang P; Hamel J; Ashton F; Ryan A
    Infect Immun; 1985 Nov; 50(2):510-6. PubMed ID: 3932211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.
    Moe GR; Zuno-Mitchell P; Lee SS; Lucas AH; Granoff DM
    Infect Immun; 2001 Jun; 69(6):3762-71. PubMed ID: 11349041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.